Nrf2 defense pathway: Experimental evidence for its protective role in epilepsy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective: Epigenetic mechanisms involved in transcriptional regulation of multiple molecular pathways are potentially attractive therapeutic interventions for epilepsy, because single target therapies are unlikely to provide both anticonvulsant and disease‐modifying effects. Methods: A selection of epilepsy‐related gene expression data sets were retrieved using NextBio software and imported to Ingenuity Pathway Analysis for transcription factor enrichment analysis. Nuclear factor erythroid 2‐related factor 2 (Nrf2)—a transcription factor that promotes the expression of numerous antioxidant, anti‐inflammatory, and neuroprotective proteins—was identified as a candidate for confirmation of mRNA expression in hippocampal tissue from patients with temporal lobe epilepsy and in mice following pilocarpine‐induced status epilepticus (SE). Human Nrf2 was overexpressed via an adeno‐associated virus (AAV) vector after the onset of spontaneous recurrent seizures (SRS) in the animals. At the end of a 5‐week continuous monitoring period for SRS, quantitative immunohistochemistry using neuronal (neuronal‐specific nuclear protein), astrocytic (glial fibrillary acidic protein), and microglial (ionized calcium binding adaptor molecule 1) markers was performed. Results: A significant increase in Nrf2 mRNA expression was observed in human epileptic hippocampal tissue. Nrf2 expression levels increased progressively in mice, reaching a peak at 72 hours after SE, and then declined. Similar expression patterns were observed for 3 Nrf2‐regulated genes: HO‐1, NQO1, and mGST. Remarkably, mice injected with AAV Nrf2 displayed significantly fewer generalized seizures, with profound reduction in microglia activation. Hippocampal neurons were preserved, whereas the number of astrocytes was unchanged. Interpretation: These findings extend the potential of Nrf2‐based therapies to epilepsy and add to the rapidly accumulating evidence from other neurodegenerative and inflammatory disease models. Ann Neurol 2013;74:560–568
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An integrative genomics approach to infer causal associations between gene expression and disease
Schadt, E. E., Lamb, J., Yang, X., Zhu, J., Edwards, S., GuhaThakurta, D., Sieberts, S. K., Monks, S., Reitman, M., Zhang, C., et al. (2005) · Nature Genetics · doi:10.1038/ng1589 · Cited by 1,043 · cited 1×
“Parallel analysis of differentially expressed genes can provide an unbiased approach to identify genes and pathways associated with genetic, environmental, or complex disease etiologies.(23,24) Given the complexity of disease TABLE .”
BackgroundExpression of Nrf2 in Neurodegenerative Diseases
Ramsey, C. P., Glass, C. A., Montgomery, M. B., Lindl, K. A., Ritson, G. P., Chia, L. A., Hamilton, R. L., Chu, C. T., & Jordan-Sciutto, K. L. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31802d6da9 · Cited by 760
Chen, P.-C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W., & Johnson, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813361106 · Cited by 579
Vargas, M. R., Johnson, D. A., Sirkis, D. W., Messing, A., & Johnson, J. A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4099-08.2008 · Cited by 479
Loss of apolipoprotein E receptor LR11 in Alzheimer disease
Scherzer, C. R., Offe, K., Gearing, M., Rees, H. D., Fang, G., Heilman, C. J., Schaller, C., Bujo, H., Levey, A. I., & Lah, J. J. (2004) · Archives of Neurology · doi:10.1001/archneur.61.8.1200 · Cited by 316 · cited 1×
“Parallel analysis of differentially expressed genes can provide an unbiased approach to identify genes and pathways associated with genetic, environmental, or complex disease etiologies.(23,24) Given the complexity of disease TABLE .”
Background
Cited by
Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy
Vezzani, A., Balosso, S., & Ravizza, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0217-x · Cited by 893
New avenues for anti-epileptic drug discovery and development
Löscher, W., Klitgaard, H., Twyman, R. E., & Schmidt, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4126 · Cited by 675
Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet
Rogawski, M. A., Löscher, W., & Rho, J. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022780 · Cited by 336
NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage
Xiong, W., MacColl Garfinkel, A. E., Li, Y., Benowitz, L. I., & Cepko, C. L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79735 · Cited by 280
Ketogenic diets, mitochondria, and neurological diseases
Gano, L. B., Patel, M., & Rho, J. M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r048975 · Cited by 277
Metadata
- Authors
- Mazzuferi, M., Kumar, G., van Eyll, J., Danis, B., Foerch, P., & Kaminski, R. M.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2013-07-03
- Volume
- 74
- Issue
- 4
- Pages
- 560-568
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1482023004
- Cited by
- 133
- References
- 5
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.